spacer
home > pmps > summer 2007 > seeing is believing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Seeing is Believing

Nicole Golomb at Secutag examines RFID as a security measure, finding that recent advances in optically variable counterfeit-resistant technologies are gaining more precedence in the pharmaceutical industry

Recent cases in the UK where counterfeit drugs appeared in the legitimate pharmacy supply chain have made one thing very clear: even the European medicine market is no longer safe and secure. Drug trade via the internet, and parallel imports in particular, involve unknown risks. Counterfeit medicines can harm people’s health and endanger their lives. The US Government has therefore subsidised radio frequency identification (RFID) as a promising technology in the fight against fake drugs. Initially, RFID seemed to be the silver bullet for ending drug counterfeiting. However, people have become increasingly disillusioned with the reality of this technology, and the trend is once again for physical security measures.

Micro colour-code systems, for instance, are designed to help protect against the growing problem of counterfeiting. Since May 2007, three cases of counterfeit drugs have been discovered in Britain: fake versions of the antipsychotic olanzapine, forged bicalutamide, (used to treat prostate cancer) and the blood-thinner clopidogrel all appeared in the legitimate supply chain. All counterfeit pharmaceutical products had too little active drug content which can lead to unforeseen side effects and considerably harm people’s health.

The Medicines and Healthcare Products Regulatory Agency (MHRA) therefore immediately started a nationwide recall. The manufacturer provided detailed information about the drugs, which helped the MHRA to find out exactly when the pharmaceuticals were delivered and to identify them from the lot numbers. There is hope that all fake drugs will be found in order to prevent further harm: “We take this very seriously and a criminal investigation is being carried out,” said a MHRA spokesperson. Meanwhile, one person was arrested.

For many years, the European medicine market was considered completely safe. The phrase ‘drug piracy’ referred primarily to the uncontrolled markets in the developing countries, or the emerging markets in Asia and Africa, where selling crude mixtures of backing powder and chalk, with copied, low-dose or ineffective ingredients has become a common problem. Until now, the issue of counterfeit drugs has played a minor role in Europe. However, the latest EU statistics show that the number of incidences of fake medicines is rising. In 2006, European customs seized 2.5 million counterfeit pharmaceutical products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nicole Golomb is Marketing and Sales Manager for anti-counterfeit systems at 3S Simons Security Systems GmbH, Germany. Nicole is in charge of the management of the specific customer projects dealing with individual applications of the micro colour-code system SECUTAG® on branded articles. Furthermore, she is responsible for the analysis of processing technologies in specific industries and the product protection system’s integration in the different branches.
spacer
Nicole Golomb
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement